Treating Lower Respiratory Infection with Imported and Domestic Cefoperazone/Sulbactam Sodium:Cost-effectiveness Analyses
- VernacularTitle:进口与国产头孢哌酮/舒巴坦钠治疗下呼吸道感染的成本-效果分析
- Author:
An LIU
- Publication Type:Journal Article
- Keywords:
Cefoperazone/sulbactam sodium;
Imported;
Domestic;
Lower respiratory infection;
Cost-effectiveness analysis
- From:
China Pharmacy
2001;0(07):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the cost-effectiveness of imported and domestic cefoperazone/sulbactam sodium in treating lower respiratory infection.METHODS:60patients with lower respiratory infections were ascribed to receive im-ported or domestic cefoperazone/sulbactam sodium(2∶1)respectively,the curative effects of the drugs were monitored and evaluated by cost-effectiveness analysis.RESULTS:The costs of the two groups were3164.00yuan and828.80yuan,re-spectively(P0.05),respectively;The cost-effectiveness ratios were37.98and10.36,respectively;And the incremental cost-effectiveness ratio of the imported group vs.the domestic group was707.64.CONCLUSION:Domestic cefoperazone/sulbactam sodium is a more economical choice.
